Table 2.
Model 1 |
Model 2 |
Model 3 |
Model 4 |
|||||
---|---|---|---|---|---|---|---|---|
OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | OR (95% CI) | P Value | |
Gender: female | 0.23 (0.12-0.47) | <.001 | 0.23 (0.11-0.46) | <.001 | 0.23 (0.12-0.47) | <.001 | 0.23 (0.11-0.47) | <.001 |
Age: 1 y | 1.08 (1.05-1.11) | <.001 | 1.08 (1.05-1.11) | <.001 | 1.07 (1.04-1.10) | <.001 | 1.07 (1.03-1.10) | <.001 |
Barthel Index, 5 points | 1.13 (1.05-1.22) | .002 | 1.12 (1.04-1.21) | .004 | 1.12 (1.04-1.21) | .005 | 1.11 (1.03-1.20) | .008 |
qSOFA: 1 point | 1.28 (0.87-1.90) | .21 | 1.34 (0.90-2.00) | .14 | 1.29 (0.87-1.93) | .21 | ||
Polypharmacy: ≥5 drugs | 2.05 (1.07-3.92) | .030 | 1.54 (0.77-3.08) | .23 | ||||
Comorbidity: ≥3 diseases | 2.15 (1.08-4.30) | .030 |
Model 1: adjusted by gender, age, and Barthel; model 2: adds qSOFA to model 1; model 3: adds polypharmacy (≥5 drugs) to model 2; model 4: adds ≥3 morbidities to model 3.